<DOC>
	<DOCNO>NCT01441869</DOCNO>
	<brief_summary>Study healthy subject measure amount drug blood dose different saxagliptin / metformin product .</brief_summary>
	<brief_title>Study Healthy Subjects Measure Amount Drug Blood After Dosing With Different Saxagliptin / Metformin Produc</brief_title>
	<detailed_description>Bioequivalence Study Fixed-dose Combination Saxagliptin/Metformin XR Tablets Relative Saxagliptin ( Onglyzaï¿½ ) Tablets Australia-sourced Diabex XR Tablets Coadministered Healthy Subjects Fed State During Steady-state Administration</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision sign date informed consent prior study specific procedure Males female age 18 55 year ( inclusive ) weight least 50 kg body mass index ( BMI ) 18 35 kg/m2 , inclusive Females must negative urine pregnancy test screen negative serum pregnancy test admission unit , must lactate , must use acceptable method contraception least 1 month dose Female volunteer childbearing potential ( include perimenopausal woman menstrual period within 1 year ) must use appropriate birth control ( define method result low failure rate , ie , le 1 % per year Oral contraceptive hormone replacement medication allow study use together barrier contraceptive method . History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug ( except cholecystectomy ) Glomerular filtration rate le 60 mL/min ( estimate screen ) Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational product ( IP ) History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator ( eg , seasonal allergy ) history hypersensitivity drug similar chemical structure class saxagliptin metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Phase 1 , Healthy male volunteer , pharmacokinetics , saxagliptin/ metformin , Diabex</keyword>
</DOC>